KR101082262B1 - Composition comprising an extract of black ginseng showing anti-aging activity - Google Patents
Composition comprising an extract of black ginseng showing anti-aging activity Download PDFInfo
- Publication number
- KR101082262B1 KR101082262B1 KR1020060125472A KR20060125472A KR101082262B1 KR 101082262 B1 KR101082262 B1 KR 101082262B1 KR 1020060125472 A KR1020060125472 A KR 1020060125472A KR 20060125472 A KR20060125472 A KR 20060125472A KR 101082262 B1 KR101082262 B1 KR 101082262B1
- Authority
- KR
- South Korea
- Prior art keywords
- ginseng
- extract
- black ginseng
- black
- hours
- Prior art date
Links
- 241000208340 Araliaceae Species 0.000 title claims abstract description 92
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 title claims abstract description 92
- 235000003140 Panax quinquefolius Nutrition 0.000 title claims abstract description 92
- 235000008434 ginseng Nutrition 0.000 title claims abstract description 92
- 239000000284 extract Substances 0.000 title claims abstract description 17
- 230000003712 anti-aging effect Effects 0.000 title abstract description 9
- 239000000203 mixture Substances 0.000 title description 30
- 235000020710 ginseng extract Nutrition 0.000 claims abstract description 35
- 230000003078 antioxidant effect Effects 0.000 claims abstract description 25
- 239000003963 antioxidant agent Substances 0.000 claims abstract description 12
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 27
- 238000001035 drying Methods 0.000 claims description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
- 239000002021 butanolic extract Substances 0.000 claims description 13
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 12
- 238000010025 steaming Methods 0.000 claims description 11
- 239000004480 active ingredient Substances 0.000 claims description 9
- 230000000694 effects Effects 0.000 claims description 6
- 238000005406 washing Methods 0.000 claims description 3
- 238000010298 pulverizing process Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 abstract description 15
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 12
- 235000013376 functional food Nutrition 0.000 abstract description 11
- 235000002789 Panax ginseng Nutrition 0.000 description 19
- 238000002360 preparation method Methods 0.000 description 16
- 239000000401 methanolic extract Substances 0.000 description 15
- 238000000034 method Methods 0.000 description 13
- 239000004615 ingredient Substances 0.000 description 10
- 235000006708 antioxidants Nutrition 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 9
- 239000000796 flavoring agent Substances 0.000 description 9
- 238000009472 formulation Methods 0.000 description 9
- 229930182490 saponin Natural products 0.000 description 9
- 235000017709 saponins Nutrition 0.000 description 9
- 150000007949 saponins Chemical class 0.000 description 9
- 235000013361 beverage Nutrition 0.000 description 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
- 230000002000 scavenging effect Effects 0.000 description 8
- 239000000546 pharmaceutical excipient Substances 0.000 description 7
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 239000002775 capsule Substances 0.000 description 6
- 235000013305 food Nutrition 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 239000003826 tablet Substances 0.000 description 6
- 238000007796 conventional method Methods 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 235000019634 flavors Nutrition 0.000 description 5
- 229940097156 peroxyl Drugs 0.000 description 5
- 239000008213 purified water Substances 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 4
- 239000005977 Ethylene Substances 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 235000013355 food flavoring agent Nutrition 0.000 description 4
- 239000007789 gas Substances 0.000 description 4
- 235000019359 magnesium stearate Nutrition 0.000 description 4
- CMFNMSMUKZHDEY-UHFFFAOYSA-N peroxynitrous acid Chemical compound OON=O CMFNMSMUKZHDEY-UHFFFAOYSA-N 0.000 description 4
- 229930003231 vitamin Natural products 0.000 description 4
- 235000013343 vitamin Nutrition 0.000 description 4
- 239000011782 vitamin Substances 0.000 description 4
- 229940088594 vitamin Drugs 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 3
- 238000011047 acute toxicity test Methods 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 235000013402 health food Nutrition 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 description 3
- 229940041476 lactose 100 mg Drugs 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000011707 mineral Substances 0.000 description 3
- 235000010755 mineral Nutrition 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 235000012222 talc Nutrition 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 150000003722 vitamin derivatives Chemical class 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 239000004386 Erythritol Substances 0.000 description 2
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 244000299461 Theobroma cacao Species 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 235000014121 butter Nutrition 0.000 description 2
- 238000013329 compounding Methods 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229920001971 elastomer Polymers 0.000 description 2
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 2
- 235000019414 erythritol Nutrition 0.000 description 2
- 229940009714 erythritol Drugs 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 235000015203 fruit juice Nutrition 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 230000002489 hematologic effect Effects 0.000 description 2
- 241000411851 herbal medicine Species 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- 239000003002 pH adjusting agent Substances 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- RBCOYOYDYNXAFA-UHFFFAOYSA-L (5-hydroxy-4,6-dimethylpyridin-3-yl)methyl phosphate Chemical compound CC1=NC=C(COP([O-])([O-])=O)C(C)=C1O RBCOYOYDYNXAFA-UHFFFAOYSA-L 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- NCGICGYLBXGBGN-UHFFFAOYSA-N 3-morpholin-4-yl-1-oxa-3-azonia-2-azanidacyclopent-3-en-5-imine;hydrochloride Chemical group Cl.[N-]1OC(=N)C=[N+]1N1CCOCC1 NCGICGYLBXGBGN-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 208000031648 Body Weight Changes Diseases 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- 241000371652 Curvularia clavata Species 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 239000001512 FEMA 4601 Substances 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical group OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 230000002292 Radical scavenging effect Effects 0.000 description 1
- HELXLJCILKEWJH-SEAGSNCFSA-N Rebaudioside A Natural products O=C(O[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]1(C)[C@@H]2[C@](C)([C@H]3[C@@]4(CC(=C)[C@@](O[C@H]5[C@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@H](O)[C@@H](CO)O5)(C4)CC3)CC2)CCC1 HELXLJCILKEWJH-SEAGSNCFSA-N 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 238000011394 anticancer treatment Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 230000003416 augmentation Effects 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000010876 biochemical test Methods 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 230000004579 body weight change Effects 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 230000009172 bursting Effects 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 229940037769 calcium carbonate 100 mg Drugs 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 229960002079 calcium pantothenate Drugs 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 229940069647 citric acid 1000 mg Drugs 0.000 description 1
- FDJOLVPMNUYSCM-UVKKECPRSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2,7, Chemical compound [Co+3].N#[C-].C1([C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)[N-]\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O FDJOLVPMNUYSCM-UVKKECPRSA-L 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 229940095079 dicalcium phosphate anhydrous Drugs 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- HELXLJCILKEWJH-UHFFFAOYSA-N entered according to Sigma 01432 Natural products C1CC2C3(C)CCCC(C)(C(=O)OC4C(C(O)C(O)C(CO)O4)O)C3CCC2(C2)CC(=C)C21OC(C1OC2C(C(O)C(O)C(CO)O2)O)OC(CO)C(O)C1OC1OC(CO)C(O)C(O)C1O HELXLJCILKEWJH-UHFFFAOYSA-N 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 239000011790 ferrous sulphate Substances 0.000 description 1
- 235000003891 ferrous sulphate Nutrition 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 235000020510 functional beverage Nutrition 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 235000001497 healthy food Nutrition 0.000 description 1
- 239000001307 helium Substances 0.000 description 1
- 229910052734 helium Inorganic materials 0.000 description 1
- SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 1
- 238000006897 homolysis reaction Methods 0.000 description 1
- 238000000185 intracerebroventricular administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 231100000668 minimum lethal dose Toxicity 0.000 description 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 238000005502 peroxidation Methods 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001508 potassium citrate Substances 0.000 description 1
- 229960002635 potassium citrate Drugs 0.000 description 1
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 1
- 235000011082 potassium citrates Nutrition 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000003642 reactive oxygen metabolite Substances 0.000 description 1
- 235000019203 rebaudioside A Nutrition 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 229960000342 retinol acetate Drugs 0.000 description 1
- 235000019173 retinyl acetate Nutrition 0.000 description 1
- 239000011770 retinyl acetate Substances 0.000 description 1
- QGNJRVVDBSJHIZ-QHLGVNSISA-N retinyl acetate Chemical compound CC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C QGNJRVVDBSJHIZ-QHLGVNSISA-N 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 235000002639 sodium chloride Nutrition 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000008227 sterile water for injection Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- JZRWCGZRTZMZEH-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/02—Antioxidant
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/302—Foods, ingredients or supplements having a functional effect on health having a modulating effect on age
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/13—Preparation or pretreatment of starting material involving cleaning, e.g. washing or peeling
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/17—Preparation or pretreatment of starting material involving drying, e.g. sun-drying or wilting
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Nutrition Science (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Medical Informatics (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
본 발명은 인삼을 이용하여 제조한 흑삼으로부터 수득한 흑삼 추출물에 관한 것으로, 흑삼의 추출물은 뛰어난 항산화 효과를 나타내므로 항노화용 약학조성물 및 건강기능식품으로 이용될 수 있다.The present invention relates to a black ginseng extract obtained from black ginseng prepared using ginseng, and the extract of black ginseng exhibits an excellent antioxidant effect and can be used as an anti-aging pharmaceutical composition and health functional food.
흑삼, 대량생산, 수삼, 항산화. Black ginseng, mass production, fresh ginseng, antioxidant.
Description
도 1은 흑삼 증숙시 사용한 옹기를 나타낸 도이다.1 is a view showing the Onggi used for steaming black ginseng.
본 발명의 목적은 인삼을 이용하여 제조한 흑삼으로부터 수득한 흑삼 추출물을 유효성분으로 함유하는 항산화 활성을 갖는 항노화용 약학조성물 및 건강기능식품을 제공하는 것이다.An object of the present invention is to provide an anti-aging pharmaceutical composition and health functional foods containing antioxidant activity containing black ginseng extract obtained from black ginseng prepared using ginseng as an active ingredient.
35억 달러 세계 인삼시장을 잡기 위하여 국내 바이오 벤처기업들이 연간 35억 달러에 달하는 세계 인삼 관련 신 물질 개발에 열을 올리고 있다. 지금까지 인삼을 기능성식품으로 표준화 해 세계 시장에서 성과를 올리고 있는 기업은 스위스 베링거잉겔하임 산하의 “파머톤사" 뿐이며 국내에서도 인삼에 대한 국가차원의 연구와 벤처업계의 상품화가 속속 진행되고 있다. To capture the $ 3.5 billion global ginseng market, Korean bio venture companies are working hard to develop new global ginseng-related materials worth $ 3.5 billion annually. So far, the only company that has standardized ginseng as a functional food and is making a profit in the global market is “Pharmaton,” a company owned by Boehringer Ingelheim, Switzerland. National research on ginseng and commercialization of the venture industry are in progress.
우리나라의 홍삼은 약 1,000년 전부터 제조된 역사적 기록을 가지고 있으며 (중국 송나라의 서긍이 저술한 고려도경에 홍삼에 대한 기록이 있음), 한의학적 전통제약기술인 수치법에 의해 가공제조된 수치생약이라 할 수 있다. 일반적으로 생약의 수치목적은 1) 독성 등 부작용의 경감, 2) 생약 성능의 개변과 약효의 증강, 3) 보관이나 저장성의 향상, 4) 맛과 냄새 교정 및 부색 등으로 알려지고 있다. 일반적으로 홍삼은 적정한 열처리 공정을 거치는 동안 2차적 성분변환이 일어나 수삼(fresh ginseng)이나 백삼에 존재하지 않는 홍삼 특유의 새로운 약효성분들이 생성되기도 하고, 어떤 활성성분은 함량 증가가 일어난다. 이렇듯 인삼의 가공방법에 따라 인삼에 존재하지 않는 새로운 성분이 생성되며 인삼에 비해서 항암작용을 비롯한 여러 가지 생리활성에 대해서 보다 우수한 효과를 나타내는 새로운 가공 인삼을 개발 할 수 있다(Okamura N. et al., Biol . Pharm . Bull., 17(2), p270, 1994). Korean red ginseng has a historical record of about 1,000 years ago. have. In general, the numerical objectives of herbal medicines are known as: 1) reducing side effects such as toxicity, 2) altering herbal properties and enhancing drug efficacy, 3) improving storage and storage, and 4) correcting taste and odor and color. In general, red ginseng undergoes a second ingredient conversion during an appropriate heat treatment process, thereby generating new active ingredients unique to red ginseng or fresh ginseng, and some active ingredients increase in content. As such, new ingredients that do not exist in ginseng are produced according to the processing method of ginseng, and new processed ginsengs having better effects on various physiological activities including anticancer activity can be developed compared to ginseng (Okamura N. et al. , Biol . Pharm . Bull. , 17 (2) , p270, 1994).
중국의 경우 백삼에는 거의 존재하지 않으며 홍삼에 소량 존재하는 인삼 사포닌인 Rg3를 대량 생산하는 방법을 개발하여 ‘Shenyi' 라는 상품명으로 항암치료를 위해 사용하고 있다.In China, it develops a method of mass-producing Rg3, a ginseng saponin, which is rarely present in white ginseng and is present in red ginseng, and is used for anticancer treatment under the trade name 'Shenyi'.
국내의 경우 기능성 인삼의 대표 제품은 지난 98년 바이오벤처기업 진생사이언스가 개발한 ‘선삼’으로써 지난 2001년 선삼정으로 개발돼 국내 건강기능성식품 시장에 본격 알려진 이후 국내는 물론 전 세계적인 발명품으로도 인정받으며 기능성 인삼의 선두주자로 자리매김 한 상태이다(Keum YS et al., Antioxidant and anti-tumor promoting activities of the methanol extract of heat-processed ginseng, Cancer Lett., 150(1), pp41-48, 2000). In Korea, the representative product of functional ginseng is 'Seonsam' developed by bio venture company Ginseng Science in 1998.It was developed as Sesamsamjeong in 2001 and recognized in domestic health functional food market. It has been established as a leader in functional ginseng (Keum YS et al., Antioxidant and anti-tumor promoting activities of the methanol extract of heat-processed ginseng, Cancer Lett ., 150 (1) , pp 41-48, 2000).
이 밖에도 한국생명공학연구원과 바이오벤처기업 비티진이 공동 개발한 ‘황삼EX’, ㈜남일농장 인삼영농조합이 바이오벤처기업인 ㈜그린바이오와 손잡고 제품화한 ‘팽화홍삼’, 남양알로에에서 분사한 ㈜유니젠은 최근 미국 UPI사와 공동으로 개발한 `바이오맥스', (주)CJ의 ‘식스플러스’, (주)일동제약의 ‘황삼’ 과 같은 여러 종류의 가공인삼이 개발되고 있다. In addition, 'Hwangsam EX' co-developed by Korea Research Institute of Biotechnology and biotechnology company Beatijin, Namseng Farm Co., Ltd., 'Ginseng Red Ginseng' produced by joining Biobio, Green Bio Co., Ltd., and Unigen Co., Ltd. Recently, various types of processed ginseng are being developed, such as Biomax, which was developed jointly with UPI in the US, Six Plus of CJ, and Yellow Ginseng of Ildong Pharm.
또한, 최근에는 인삼의 활성성분 함량을 더욱 높이기 위한 노력의 결과로써 증숙법의 하나인 한약재의 가공방법 중 물과 불을 함께 사용하는 것으로 가장 대표적인 방법인 구증구폭의 원리를 이용한 흑삼이 개발된 바 있으며(한국공개특허공보 특 2003-0005089; 흑삼과 흑미삼의 제조방법), 본 연구실에서는 이 방법에 비해서 시간적으로 단축되고 대량 생산이 가능한 표준화된 흑삼의 제조방법(대한민국 특허출원 제 10-2006-0044066; 신규한 흑삼의 제조방법 및 이를 함유하는 조성물) 및 흑인삼엽의 제조방법(대한민국 특허출원 제 10-2006-76232; 신규제조방법으로 제조된 흑인삼엽 및 이의 추출물을 함유하는 항노화용 약학 조성물 및 건강기능식품)에 대해서 특허를 출원한 바 있다. In addition, recently, as a result of efforts to further increase the active ingredient content of ginseng, black ginseng using the principle of Gugugugupo, which is the most representative method of using water and fire, was developed. (Korean Patent Laid-Open Publication No. 2003-0005089; manufacturing method of black ginseng and black rice ginseng), and in this laboratory, a standardized method of manufacturing black ginseng which can be shortened in time and mass production is possible (Korean Patent Application No. 10-2006- New black ginseng production method and composition containing the same) and black ginseng leaf manufacturing method (Korean Patent Application No. 10-2006-76232; Black ginseng leaf produced by the new manufacturing method and an anti-aging pharmaceutical composition containing the extract thereof and Health functional food) has been applied for a patent.
이와 같이 인삼의 프리미엄화 시대를 맞이하여 본 발명자는 흑삼 추출물이 다량의 인삼 사포닌을 함유하며, 뛰어난 항산화 효과를 나타냄을 확인하여 본 발명을 완성하였다. As such, the present inventors have completed the present invention by confirming that black ginseng extract contains a large amount of ginseng saponin and exhibits an excellent antioxidant effect.
본 발명의 목적은 인삼을 이용하여 제조한 흑삼으로부터 수득한 흑삼 추출물 을 함유하는 항산화 활성을 나타내는 항노화용 약학 조성물 및 건강기능식품을 제공하는데 있다.An object of the present invention is to provide an anti-aging pharmaceutical composition and health functional food containing antioxidant activity containing black ginseng extract obtained from black ginseng prepared using ginseng.
상기의 목적을 달성하기 위하여, 본 발명은 인삼을 건조, 증숙, 가열 및 건조하는 공정을 통해 제조한 흑삼으로부터 수득된 흑삼 추출물을 유효성분으로 함유하는 항산화 활성을 갖는 항노화용 약학조성물 및 건강기능식품을 제공한다.In order to achieve the above object, the present invention is an anti-aging pharmaceutical composition and health functional food containing antioxidant activity containing black ginseng extract obtained from black ginseng prepared by drying, steaming, heating and drying ginseng as an active ingredient. To provide.
이하, 본 발명을 상세히 설명한다.Hereinafter, the present invention will be described in detail.
본 발명의 흑삼 및 이의 추출물은 하기와 같은 공정을 통하여 제조될 수 있다. Black ginseng and extracts thereof of the present invention may be prepared through the following process.
본 발명의 3 내지 7년근, 바람직하게는 5년근 수삼을 세척 후, 20 내지 60℃, 바람직하게는 35 내지 55℃의 온도에서 12 내지 36시간, 바람직하게는 20 내지 28시간 건조하는 1차 건조공정; 옹기에 넣어 예열시간을 제외하고 60 내지 120℃, 바람직하게는 85 내지 105℃의 온도에서 3 내지 9시간, 바람직하게는 5 내지 7시간 동안 증숙하는 1차 증숙공정; 40 내지 80℃, 바람직하게는 50 내지 70℃의 온도에서 6 내지 18시간, 바람직하게는 9 내지 15시간 동안 건조시키는 2차 건조공정; 85 내지 135℃, 바람직하게는 95 내지 125℃의 온도에서 3 내지 9시간, 바람직하게는 5 내지 7시간 동안 증숙하는 2차 증숙공정; 8 내지 16시간, 바람직하게는 10 내지 14시간 동안 건조하는 3차 건조공정을 포함함을 특징으로 하는 흑삼을 제조할 수 있다. After washing 3 to 7 years old root, preferably 5 years old root ginseng of the present invention, primary drying is carried out at 20 to 60 ° C, preferably 35 to 55 ° C for 12 to 36 hours, preferably 20 to 28 hours. fair; Primary steaming step of steaming for 3 to 9 hours, preferably 5 to 7 hours at a temperature of 60 to 120 ℃, preferably 85 to 105 ℃ except for preheating time in the Onggi; A secondary drying step of drying at a temperature of 40 to 80 ° C., preferably 50 to 70 ° C. for 6 to 18 hours, preferably 9 to 15 hours; A secondary steaming step of steaming at a temperature of 85 to 135 ° C, preferably 95 to 125 ° C for 3 to 9 hours, preferably 5 to 7 hours; Black ginseng may be prepared, including a third drying step of drying for 8 to 16 hours, preferably 10 to 14 hours.
또한 상기 방법으로 제조된 흑삼의 추출물을 수득하는 방법을 자세히 설명하면, 상기 제조 방법으로 제조된 흑삼을 분쇄한 후, 흑삼의 약 3 내지 7배, 바람직하게는 4 내지 6배 질량의 물을 가하여, 실온에서 3 내지 7시간 방치한 후, 메탄올을 0.5 내지 2ℓ를 가하여, 3시간씩 3회 환류 추출하였다. 추출한 용액을 실온까지 냉각시킨 후 여과한 뒤 감압 농축기를 이용하여 메탄올을 제거하여 본 발명의 흑삼 추출물을 수득할 수 있다.In addition, the method for obtaining the extract of the black ginseng prepared by the above method will be described in detail. After crushing the black ginseng prepared by the above method, water of about 3 to 7 times, preferably 4 to 6 times the mass of black ginseng is added thereto. After standing at room temperature for 3 to 7 hours, 0.5-2 L of methanol was added and the mixture was extracted under reflux three times for three hours. The extracted solution is cooled to room temperature, filtered and the methanol is removed using a reduced pressure concentrator to obtain the black ginseng extract of the present invention.
상기 제조 방법에 의해 제조된 흑삼 추출물은 음건, 냉동건조 등의 당업계에 통상적인 건조방법을 통하여 건조한 후, 미세입자, 바람직하게는 약 50㎛ 내지 200㎛의 입자크기로 분쇄, 분말화하는 공정을 통하여 당업계에 잘 알려진 부형제 또는 담체를 이용하여 환제, 캅셀제, 정제 등의 조성물로 제조할 수 있다.The black ginseng extract prepared by the manufacturing method is dried through a drying method common in the art such as shade drying, freeze drying, and then pulverized and powdered into fine particles, preferably a particle size of about 50 μm to 200 μm. Through the use of excipients or carriers well known in the art can be prepared in compositions such as pills, capsules, tablets.
상기 방법에 의해 제조된 흑삼은 생약 분쇄기를 이용하여 미세분말, 바람직하게는 약 50~200㎛ 크기의 분말로 분쇄하여 각종제제의 원료로 사용할 수 있다.The black ginseng prepared by the above method may be used as a raw material for various preparations by grinding into fine powder, preferably powder of about 50 to 200 μm, using a herbal medicine grinder.
본 발명은 인삼 자체뿐만 아니라 인삼잎에도 적용될 수 있다. 인삼잎은 지금까지 약용으로 사용하지는 않고 그냥 버리거나 사료용으로 사용되었으며 일부가 향장품 또는 식품의 원료로 사용되어 왔을 뿐이나, 인삼잎 추출물을 본 발명에서와 같은 방법으로 가열, 가압처리 할 경우 약효가 훨씬 강화되므로 이제까지의 인삼잎의 용도에는 물론이고 약용으로도 사용될 수 있다. The present invention can be applied to ginseng leaves as well as ginseng itself. Although ginseng leaves have not been used for medicinal purposes, they have been discarded or used for feed, and some of them have been used as raw materials for cosmetics or foods. However, when ginseng leaf extracts are heated and pressurized in the same way as in the present invention, the medicinal effect is much better. Since it is fortified, it can be used for medicinal purposes as well as the ever-used ginseng leaves.
상기 방법으로 제조된 흑삼은 기존의 수삼이나 백삼, 또는 홍삼에는 없거나, 극미량으로 존재하던 활성 성분의 함량을 증강시킴을 특징으로 한다.The black ginseng prepared by the above method is characterized in that the existing ginseng, white ginseng, or red ginseng does not exist or enhances the content of the active ingredient present in trace amounts.
본 발명의 제조방법으로 제조된 흑삼 추출물은 기존의 홍삼에 비하여 더욱 강한 항산화 효과를 나타냄을 특징으로 한다.Black ginseng extract prepared by the production method of the present invention is characterized by showing a stronger antioxidant effect than conventional red ginseng.
따라서, 본 발명은 상기 추출방법으로부터 제조되는 흑삼 추출물을 유효성분으로 함유하는 항산화효과를 나타내는 항산화제, 항노화용 약학조성물 및 건강기능식품을 제공한다.Therefore, the present invention provides an antioxidant, an anti-aging pharmaceutical composition, and a health functional food containing the black ginseng extract prepared from the extraction method as an active ingredient.
본 발명의 흑삼 추출물을 함유하는 약학조성물은, 조성물 총 중량에 대하여 상기 흑삼 추출물을 0.1 내지 50 중량%로 포함한다.The pharmaceutical composition containing the black ginseng extract of the present invention comprises 0.1 to 50% by weight of the black ginseng extract based on the total weight of the composition.
본 발명의 흑삼 추출물을 포함하는 약학조성물은 약학적 조성물의 제조에 통상적으로 사용하는 적절한 담체, 부형제 및 희석제를 더 포함할 수 있다.The pharmaceutical composition comprising the black ginseng extract of the present invention may further include suitable carriers, excipients and diluents commonly used in the preparation of pharmaceutical compositions.
본 발명에 따른 흑삼 추출물을 포함하는 약학조성물은, 각각 통상의 방법에 따라 산제, 과립제, 정제, 캡슐제, 현탁액, 에멀젼, 시럽, 에어로졸 등의 경구형 제형, 외용제, 좌제 및 멸균 주사용액의 형태로 제형화하여 사용될 수 있다. 추출물을 포함하는 조성물에 포함될 수 있는 담체, 부형제 및 희석제로는 락토즈, 덱스트로즈, 수크로스, 솔비톨, 만니톨, 자일리톨, 에리스리톨, 말티톨, 전분, 아카시아 고무, 알지네이트, 젤라틴, 칼슘 포스페이트, 칼슘 실리케이트, 셀룰로즈, 메틸 셀룰로즈, 미정질 셀룰로스, 폴리비닐 피롤리돈, 물, 메틸히드록시벤조에이트, 프로필히드록시벤조에이트, 탈크, 마그네슘 스테아레이트 및 광물유를 들 수 있다. 제제화할 경우에는 보통 사용하는 충진제, 증량제, 결합제, 습윤제, 붕해제, 계면활성제 등의 희석제 또는 부형제를 사용하여 조제된다. 경구투여를 위한 고형제제에는 정제, 환제, 산제, 과립제, 캡슐제 등이 포함되며, 이러한 고형제제는 상기 추출물에 적어도 하나 이상의 부형제 예를 들면, 전분, 칼슘카보네이트 (calcium carbonate), 수크로스(sucrose) 또는 락토오스(lactose), 젤라틴 등을 섞어 조제된다. 또한 단순한 부형제 이외에 마그네슘 스테아레이트, 탈크 같은 윤활제들도 사용된다. 경구를 위한 액상 제제로는 현탁제, 내용액제, 유제, 시럽제 등이 해당되는데 흔히 사용되는 단순희석제인 물, 리퀴드 파라핀 이외에 여러 가지 부형제, 예를 들면 습윤제, 감미제, 방향제, 보존제 등이 포함될 수 있다. 비경구 투여를 위한 제제에는 멸균된 수용액, 비수성용제, 현탁제, 유제, 동결건조 제제, 좌제가 포함된다. 비수성용제, 현탁제로는 프로필렌글리콜(propylene glycol), 폴리에틸렌 글리콜, 올리브 오일과 같은 식물성 기름, 에틸올레이트와 같은 주사 가능한 에스테르 등이 사용될 수 있다. 좌제의 기제로는 위텝솔(witepsol), 마크로골, 트윈 (tween) 61, 카카오지, 라우린지, 글리세로제라틴 등이 사용될 수 있다.Pharmaceutical compositions comprising black ginseng extract according to the present invention, respectively, in the form of powder, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols, oral formulations, external preparations, suppositories, and sterile injectable solutions according to a conventional method. Can be formulated and used. Examples of carriers, excipients and diluents that can be included in the composition containing the extract include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate , Cellulose, methylcellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil. When formulated, diluents or excipients such as fillers, extenders, binders, wetting agents, disintegrating agents, and surfactants are usually used. Solid preparations for oral administration include tablets, pills, powders, granules, capsules and the like, and such solid preparations may include at least one excipient such as starch, calcium carbonate and sucrose in the extract. ) Or lactose, gelatin and the like are mixed. In addition to simple excipients, lubricants such as magnesium stearate and talc are also used. Oral liquid preparations include suspensions, solvents, emulsions, and syrups, and may include various excipients, such as wetting agents, sweeteners, fragrances, and preservatives, in addition to commonly used simple diluents such as water and liquid paraffin. . Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations, suppositories. As the non-aqueous solvent and suspending agent, propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate and the like can be used. As the base of the suppository, witepsol, macrogol, tween 61, cacao butter, laurin butter, glycerogelatin and the like can be used.
본 발명의 흑삼 추출물의 바람직한 투여량은 환자의 상태 및 체중, 질병의 정도, 약물형태, 투여경로 및 기간에 따라 다르지만, 당업자에 의해 적절하게 선택될 수 있다. 그러나 바람직한 효과를 위해서, 본 발명의 추출물은 1일 0.2 내지 200㎎/kg으로, 바람직하게는 2 내지 100㎎/kg으로 투여하는 것이 좋다. 투여는 하루에 한번 투여할 수도 있고, 수회 나누어 투여할 수도 있다. 상기 투여량은 어떠한 면으로든 본 발명의 범위를 한정하는 것은 아니다.The preferred dosage of the black ginseng extract of the present invention depends on the condition and weight of the patient, the extent of the disease, the form of the drug, the route of administration and the duration, and may be appropriately selected by those skilled in the art. However, for the preferred effect, the extract of the present invention is preferably administered at 0.2 to 200 mg / kg, preferably 2 to 100 mg / kg. Administration may be administered once a day or may be divided several times. The dosage does not limit the scope of the invention in any aspect.
본 발명의 흑삼 추출물은 쥐, 생쥐, 가축, 인간 등의 포유동물에 다양한 경로로 투여될 수 있다. 투여의 모든 방식은 예상될 수 있는데, 예를 들면, 경구, 직장 또는 정맥, 근육, 피하, 자궁내 경막 또는 뇌혈관내 (intracerebroventricular) 주사에 의해 투여될 수 있다. Black ginseng extract of the present invention can be administered to various mammals such as mice, mice, livestock, humans. All modes of administration can be expected, for example by oral, rectal or intravenous, intramuscular, subcutaneous, intrauterine dural or intracerebroventricular injection.
본 발명의 흑삼 추출물은 독성 및 부작용이 거의 없으므로 예방 또는 치료의 목적으로 장기간 복용시에도 안심하고 사용할 수 있다.Black ginseng extract of the present invention has little toxicity and side effects, so can be used with confidence even for long-term use for the purpose of prevention or treatment.
본 발명은 항산화 효과를 나타내는 흑삼 추출물을 유효성분으로 함유하는 항산화 활성을 갖는 항노화용 건강기능식품을 제공한다.The present invention provides an anti-aging health functional food having antioxidant activity containing black ginseng extract showing an antioxidant effect as an active ingredient.
본 발명의 흑삼 추출물을 첨가할 수 있는 식품으로는, 예를 들어, 각종 식품류, 음료, 껌, 차, 비타민 복합제, 건강 기능성 식품류 등이 있다. Examples of the food to which the black ginseng extract of the present invention can be added include various foods, beverages, gums, teas, vitamin complexes, and health functional foods.
또한, 항산화 효과를 목적으로 식품 또는 음료에 첨가될 수 있다. 이 때, 식품 또는 음료 중의 상기 흑삼 추출물의 양은 전체 식품 중량의 0.01 내지 15 중량%로 가할 수 있으며, 건강 음료 조성물은 100 ㎖를 기준으로 0.02 내지 5g, 바람직하게는 0.3 내지 1g의 비율로 가할 수 있다. It may also be added to foods or beverages for the purpose of antioxidant effects. At this time, the amount of the black ginseng extract in the food or beverage may be added in 0.01 to 15% by weight of the total food weight, the health beverage composition may be added in a ratio of 0.02 to 5g, preferably 0.3 to 1g based on 100ml have.
본원에서 정의되는 식품보조첨가제는 당업계에 통상적인 식품첨가제, 예를 들어 향미제, 풍미제, 착색제, 충진제, 안정화제 등을 포함하며, 하기에 예시한다.Food supplement additives as defined herein include food additives customary in the art, such as flavorings, flavors, colorants, fillers, stabilizers, and the like, and are exemplified below.
본 발명의 건강 기능성 음료 조성물은 지시된 비율로 필수 성분으로서 상기 흑삼 추출물을 함유하는 외에는 다른 성분에는 특별한 제한이 없으며 통상의 음료와 같이 여러 가지 향미제 또는 천연 탄수화물 등을 추가 성분으로서 함유할 수 있다. 상술한 천연 탄수화물의 예는 모노사카라이드, 예를 들어, 포도당, 과당 등; 디사카라이드, 예를 들어 말토스, 슈크로스 등; 및 폴리사카라이드, 예를 들어 덱스트린, 시클로덱스트린 등과 같은 통상적인 당, 및 자일리톨, 소르비톨, 에리트리톨 등의 당알콜이다. 상술한 것 이외의 향미제로서 천연 향미제(타우마틴, 스테비아 추출물(예를 들어 레바우디오시드 A, 글리시르히진등) 및 합성 향미제(사카린, 아스파르탐 등)를 유리하게 사용할 수 있다. 상기 천연 탄수화물의 비율은 본 발명의 조성물 100 ㎖당 일반적으로 약 1 내지 20g, 바람직하게는 약 5 내지 12g이다.The health functional beverage composition of the present invention is not particularly limited to other ingredients except for containing the black ginseng extract as essential ingredients in the indicated ratios, and may contain various flavors or natural carbohydrates as additional ingredients, such as ordinary drinks. . Examples of the above-mentioned natural carbohydrates include monosaccharides such as glucose, fructose and the like; Disaccharides such as maltose, sucrose and the like; And conventional sugars such as polysaccharides such as dextrin, cyclodextrin, and sugar alcohols such as xylitol, sorbitol, and erythritol. As flavoring agents other than those mentioned above, natural flavoring agents (tauumatin, stevia extract (for example, rebaudioside A, glycyrrhizin, etc.) and synthetic flavoring agents (saccharin, aspartame, etc.) can be advantageously used. The proportion of natural carbohydrates is generally about 1-20 g, preferably about 5-12 g per 100 ml of the composition of the present invention.
상기 외에 본 발명의 흑삼 추출물은 여러 가지 영양제, 비타민, 광물(전해질), 합성 풍미제 및 천연 풍미제 등의 풍미제, 착색제 및 중진제(치즈, 초콜릿 등), 펙트산 및 그의 염, 알긴산 및 그의 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알콜, 탄산 음료에 사용되는 탄산화제 등을 함유할 수 있다. 그밖에 본 발명의 추출물은 천연 과일 주스 및 과일 주스 음료 및 야채 음료의 제조를 위한 과육을 함유할 수 있다. 이러한 성분은 독립적으로 또는 조합하여 사용할 수 있다. 이러한 첨가제의 비율은 그렇게 중요하진 않지만 본 발명의 추출물 100 중량부 당 0 내지 약 20 중량부의 범위에서 선택되는 것이 일반적이다.In addition to the above, black ginseng extract of the present invention is a variety of nutrients, vitamins, minerals (electrolyte), synthetic flavors and natural flavors, such as flavoring agents, coloring and neutralizing agents (such as cheese, chocolate), pectic acid and salts thereof, alginic acid and Salts, organic acids, protective colloid thickeners, pH adjusting agents, stabilizers, preservatives, glycerin, alcohols, carbonation agents used in carbonated drinks, and the like. In addition, the extract of the present invention may contain natural fruit juice and fruit flesh for the production of fruit juice beverages and vegetable beverages. These components can be used independently or in combination. The proportion of such additives is not so critical but is usually selected in the range of 0 to about 20 parts by weight per 100 parts by weight of the extract of the present invention.
이하, 본 발명을 하기 실시예 및 실험예에 의해 상세히 설명한다.Hereinafter, the present invention will be described in detail with reference to the following examples and experimental examples.
단, 하기 실시예 및 실험예는 본 발명을 예시하는 것일 뿐, 본 발명의 내용이 하기 실험예에 의해 한정되는 것은 아니다.However, the following Examples and Experimental Examples are only illustrative of the present invention, and the content of the present invention is not limited by the following Experimental Examples.
비교실시예Comparative Example 1. 홍삼 메탄올 추출물 및 1. Red Ginseng Methanol Extract and 부탄올Butanol 추출물의 제조 Preparation of Extract
(주)금산천년홍삼에서 구입한 홍삼 20g을 분쇄한 후, 100㎖의 물을 가하여 실온에서 5시간 방치한 뒤, 메탄올 1ℓ를 가하여 3시간 씩 3회 환류 추출하고, 추 출한 용액을 실온까지 냉각시키고 여과한 뒤, 감압 농축기를 이용하여 메탄올을 제거하여 홍삼 메탄올 추출물 8.1g를 수득하였다. 20 g of red ginseng purchased from Kumsan Cheonnyeon Hongsam Co., Ltd. was pulverized, and 100 ml of water was added thereto and left at room temperature for 5 hours. Then, 1 liter of methanol was added and refluxed three times for 3 hours, and the extracted solution was cooled to room temperature. After filtering and removing methanol using a vacuum concentrator, 8.1 g of red ginseng methanol extract was obtained.
홍삼 메탄올 추출물 4.05g에 물 200㎖를 넣어 현탁시킨 후, 에테르 200㎖을 가하여 비극성 물질을 제거하였다. 남아있는 수층에 수포화 부탄올 200㎖을 가하여 인삼에 존재하는 사포닌을 추출한 후, 부탄올을 감압농축기로 제거하여 인삼 사포닌이 다량 함유된 부탄올 추출물 0.65g를 얻었다. 200 ml of water was suspended in 4.05 g of red ginseng methanol extract, and then 200 ml of ether was added to remove the nonpolar material. 200 ml of saturated butanol was added to the remaining aqueous layer to extract saponins present in ginseng, and then, butanol was removed by a vacuum condenser to obtain 0.65 g of butanol extract containing a large amount of ginseng saponin.
상기의 홍삼 메탄올 추출물 및 부탄올 추출물을 하기 실험예 1의 항산화 실험의 비교 시료로 사용하였다.The red ginseng methanol extract and butanol extract was used as a comparative sample of the antioxidant experiment of Experimental Example 1.
실시예Example 1. 흑삼의 제조 1. Preparation of Black Ginseng
금산에서 생산되어 유통되는 5년근 수삼을 구입한 후, 수삼을 스크류 세척기에 넣고 10분간 총 3회 반복해서 세척하였다. 이 때, 세척과정 중에 거피가 되지 않도록 주의하였다. After purchasing five-year-old ginseng produced and distributed in Geumsan, the ginseng was put in a screw washer and washed three times in total for 10 minutes. At this time, care was taken not to peel during the washing process.
세척된 수삼을 건조하지 않고 증숙할 경우, 수삼이 터지는 경우가 많으므로 이를 방지하기 위하여 40℃에서 24시간 1차 건조하였다. 24시간 저온에서 말린 인삼을 증숙기로 사용한 옹기(도 1 참조)에 넣고 예열시간을 제외하고 95℃에서 6시간 1차 증숙하였다. If the washed ginseng steamed without drying, the fresh ginseng is often bursting, so it was first dried at 40 ℃ for 24 hours to prevent this. The ginseng dried at low temperature for 24 hours was placed in Onggi (see FIG. 1) using a steamer, and primary steaming was performed at 95 ° C. for 6 hours except for the preheating time.
예열시간이라 함은 옹기에서 수증기가 새어 나오는 데까지의 시간으로 통상 30여분 소요되었다. 열선이 내장된 건조기의 내부온도를 60℃로 유지시킨 후 팬을 돌리면서 골고루 인삼을 12시간 동안 2차 건조시킨 후, 다시 115℃에서 6시간 2차 증숙한 후, 건조기에서 12시간 3차 건조시켜 본 발명의 흑삼을 제조하였다. The preheating time is the time it takes for the steam to leak out from the pot and it usually takes about 30 minutes. After maintaining the internal temperature of the dryer with a built-in heating wire at 60 ℃, while drying the second ginseng evenly while rotating the fan for 12 hours, and then steamed for 2 hours at 115 ℃ for 2 hours, and then 3 times drying in the dryer for 12 hours To prepare a black ginseng of the present invention.
실시예Example 2. 흑삼 메탄올 추출물 및 2. Black Ginseng Methanol Extract and 부탄올Butanol 추출물의 제조 Preparation of Extract
상기의 실시예 1의 방법으로 제조된 흑삼 20g을 취하여 분쇄한 후, 100㎖의 물을 넣고 실온에서 5시간 방치한 뒤, 메탄올 1ℓ를 넣고 3시간씩 3회 환류 추출하였다. 20 g of black ginseng prepared by the method of Example 1 was taken and pulverized, 100 ml of water was added thereto, and the mixture was left at room temperature for 5 hours. Then, 1 L of methanol was added and the mixture was refluxed three times for 3 hours.
추출한 용액을 실온까지 냉각시킨 후, 여과한 뒤, 감압농축기를 이용하여 메탄올을 제거하여 흑삼 메탄올 추출물 7.4g을 수득하였다. The extracted solution was cooled to room temperature, filtered, and methanol was removed using a vacuum condenser to obtain 7.4 g of black ginseng methanol extract.
흑삼 추출물 3.2g에 물 200㎖를 넣어 현탁시킨 후, 에테르 200㎖를 가하여 비극성 물질을 제거하였다. 남아있는 수층에 수포화 부탄올 200㎖를 가하여 인삼에 존재하는 사포닌을 추출한 후 부탄올을 감압농축기로 제거하여 인삼 사포닌이 다량 함유된 부탄올 추출물 0.7g을 얻었다. 200 g of water was added and suspended in 3.2 g of black ginseng extract, and then 200 ml of ether was added to remove the nonpolar material. 200 ml of saturated butanol was added to the remaining aqueous layer to extract saponins present in ginseng, and then butanol was removed using a vacuum condenser to obtain 0.7 g of butanol extract containing a large amount of ginseng saponin.
상기의 흑삼 메탄올 추출물 및 부탄올 추출물을 하기 실시예 3의 성분 분석, 하기 실험예 1의 항산화 실험 및 하기 실험예 2의 급성독성실험의 시료로 사용하였다.The black ginseng methanol extract and butanol extract was used as a sample of the component analysis of Example 3, the antioxidant experiment of Experimental Example 1 and the acute toxicity test of Experimental Example 2 below.
실시예Example 3. 흑삼 사포닌 성분 분석 3. Analysis of Black Ginseng Saponin Components
흑삼 추출물에 존재하는 인삼사포닌의 성분을 분석하기 위하여 상기 실시예 2에서 얻은 흑삼 부탄올 추출물 20㎎을 메탄올 1㎖에 녹인 후 0.45㎛ 필터로 여과한 여액을 하기 표 1의 HPLC 분석 조건에서 성분을 분석하였다. 성분을 분석한 결 과, 흑삼 1g당 Rb1이 2.3mg, Rb2가 2.1mg, Rc가 1.3mg, Rd가 1.4mg, Re가 0.5mg, Rg1이 1.2mg, Rk1이 3.7mg, Rg5가 4.7mg, Rg3(S)이 5.4mg, Rg3(R)이 4.5mg이 존재함을 확인하였다. In order to analyze the components of ginseng saponin present in the black ginseng extract, 20 mg of the black ginseng butanol extract obtained in Example 2 was dissolved in 1 ml of methanol, and the filtrate was filtered through a 0.45 μm filter. It was. As a result of analyzing the ingredients, Rb1 2.3mg, Rb2 2.1mg, Rc 1.3mg, Rd 1.4mg, Re 0.5mg, Rg1 1.2mg, Rk1 3.7mg, Rg5 4.7mg, It was confirmed that 5.4 mg of Rg3 (S) and 4.5 mg of Rg3 (R) were present.
즉, 기존의 구증구폭의 원리를 이용하여 제조한 흑삼과 비교했을 때 우수하거나 유사한 수준으로 인삼 사포닌이 존재한다는 것을 확인할 수 있었다. That is, it was confirmed that ginseng saponin existed at an excellent or similar level when compared with the black ginseng prepared using the existing augmentation width principle.
0분(0%B), 0-10분(30% B), 10-25분(50% B), 25-40(100% B), 40-50분(100% B), 50-55분(0% B), 55-58분(0% B)A; CH 3 CN: H 2 O: 5% CH 3 COOH = 15: 80: 5, B; CH 3 CN: H 2 O = 80:20
0 minutes (0% B), 0-10 minutes (30% B), 10-25 minutes (50% B), 25-40 (100% B), 40-50 minutes (100% B), 50-55 Minute (0% B), 55-58 minutes (0% B)
실험예 1. 항산화 실험Experimental Example 1. Antioxidant Experiment
흑삼 추출물의 항산화 활성을 측정하기 위하여 TOSC(Total Oxyradical Scavenging Capacity) 분석(assay)법을 이용하여 비교실시예 1의 홍삼 추출물 및 실시예 2의 흑삼 추출물에 대하여 하기와 같이 라디칼 소거능 실험을 실시하였다.In order to measure the antioxidant activity of the black ginseng extract, a radical scavenging activity was performed on the red ginseng extract of Comparative Example 1 and the black ginseng extract of Example 2 using TOSC (Total Oxyradical Scavenging Capacity) assay.
TOSC 분석(assay)은 윈스턴 등(Winston et al., Free Radic Biol Med., Feb, 24(3), pp480-493, 1998)에 의해 제안되고 같은 저자들에 의해 수정된 방법(Regoli and Winston, Toxicol Appl Pharmacol., Apr 15, 156(2), pp96-105, 1999)을 이용하여 실시하였다. The TOSC assay is proposed by Winston et al., Free Radic Biol Med., Feb, 24 (3), pp480-493, 1998 and modified by the same authors (Regoli and Winston, Toxicol Appl Pharmacol., Apr 15, 156 (2) , pp96-105, 1999).
퍼옥실 라디칼(Peroxyl radical)은 ABAP(2,2'-azobisamidinopropane)를 35℃에서 자유라디칼반응(thermal homolysis)시켜 발생시켰고(Winston et al., Free Radic Biol Med ., Feb, 24(3), pp480-493, 1998), 하이드록실 라디칼(Hydroxyl radical)은 철(Fe)과 아스코르브산염(ascorbate)을 이용한 펜톤 반응(Fenton reaction; Winston and Cederbaum, Alcholol Clin Exp Res., 9(2), pp95-102, 1985)으로, 과산화질산염(peroxynitrite)은 SIN-1의 자연 분해(spontaneous decomposition)를 통해 발생시켰다. 발생한 각각의 활성 산소종(reactive oxygen species)은 KMBA(α-keto-γ-methiolbutyric acid)와 반응하여 에틸렌 가스(ethylene gas)를 발생하며 이 반응은 일정 범위 내에서는 온도에 따른 차이를 나타내지 않는 것으로 보고된 바 있다(Winston et al., Free Radic Biol Med., 24(3), pp480-493, 1998; Regoli and Winston, Toxicol Appl Pharmacol., 156(2), pp96-105, 1999).Peroxyl radicals were generated by thermal homolysis of ABAP (2,2'-azobisamidinopropane) at 35 ° C (Winston et al., Free Radic Biol) Med ., Feb, 24 (3), pp480-493, 1998), and hydroxyl radicals are the Fenton reaction using Fe and ascorbate (Fenton reaction; Winston and Cederbaum, Alcholol Clin Exp Res ., 9 (2), pp95-102, 1985), peroxynitrite was generated through spontaneous decomposition of SIN-1. Each reactive oxygen species generated reacts with α-keto-γ-methiolbutyric acid (KMBA) to generate ethylene gas, which does not show any temperature-dependent difference. It has been reported (Winston et al., Free Radic Biol Med ., 24 (3), pp480-493, 1998; Regoli and Winston, Toxicol Appl Pharmacol. , 156 (2), pp96-105, 1999).
반응은 최종 용량(volume) 1 ml의 반응액을 고무로 된 셉텀(rubber septum)으로 밀폐된 10 ml 용기에 넣어 진행시켰다. 에틸렌 가스(Ethylene gas) 생성 검출은 반응용기의 헤드 스페이스(head space) 내부 공기를 일정 용량(volume) 취하여 포로팩 N 컬럼(Poropack N column)과 FID(flame ionization detector)를 장착한 GC(gas chromatography)로 분석하여 실시하였다. The reaction proceeded by putting the final volume of 1 ml of the reaction solution into a sealed 10 ml container with rubber septum. Ethylene gas generation detection takes a predetermined volume of air in the head space of the reaction vessel and is equipped with a gas chromatography equipped with a Poropack N column and a flame ionization detector (FID). Was analyzed.
그 실험결과, AUC(area under the kinetic curve)는 상기 실험측정치로부터 구한 그래프를 적분(integration)하여 얻었고, TOSC값은 하기 수학식 1을 통하여 산출하였다(표 2 및 표 3 참조).As a result of the experiment, the area under the kinetic curve (AUC) was obtained by integrating a graph obtained from the experimental measurements, and the TOSC value was calculated through Equation 1 below (see Table 2 and Table 3).
∫SA = 시료 반응의 곡선으로부터 적분한 범위∫SA = range integrated from the curve of the sample response
(integrated area from the curve of the sample reaction)(integrated area from the curve of the sample reaction)
∫CA = 대조군 반응의 곡선으로부터 적분한 범위∫CA = integrated range from curve of control response
(integrated area from the curve of the control reaction)(integrated area from the curve of the control reaction)
옥시라디칼 소거능(oxyradical scavenging capacity)을 전혀 갖지 못하는 시료의 경우에는 ∫SA/∫CA = 1 이 되며, TOSC = 0 의 값을 갖는다. 반대로 ∫SA → 0 일때는, TOSC 값은 100 에 접근한다. TOSC 값은 대조군에서의 값과 비교하게 되므로 이론적으로 기기의 감도나 사용시약, 기타 반응조건에 영향을 받지 않는다. For samples that do not have any oxyradical scavenging capacity, ∫SA / ∫CA = 1 and have a value of TOSC = 0. Conversely, when ∫SA → 0, the TOSC value approaches 100. The value of TOSC is compared with the value in the control, so it is theoretically unaffected by the sensitivity of the instrument, reagents used, or other reaction conditions.
에틸렌 가스(Ethylene gas)의 검출을 위해 포로팩 N 컬럼(Poropack N column)과 FID(flame ionizing detector)를 장착한 GC를 오븐(oven) 60℃, 인젝터(injector) 180℃ 및 디텍터(detector) 180℃로 고정하고, 이동상으로는 헬륨을 30ml/분의 속도로 컬럼으로 주입하였다. 바이알(Vial)의 에틸렌 가스(ethylene gas) 정량을 위해 헤드-스페이스 법(head-space technique)을 이용하여 바이알 안의 공기를 가스 밀폐된(gas-tight) 주사기로 150 μl 취하여 가스 밀폐된(gas-tight) 주사기로 취하여 인젝터(injector)에 주입하여 실험하였다. GC equipped with Poropack N column and FID (flame ionizing detector) for the detection of ethylene gas was placed in an oven at 60 ° C, injector 180 ° C and detector 180. It was fixed at 캜 and helium was injected into the column at a rate of 30 ml / min as the mobile phase. For the determination of the ethylene gas in the vial, 150 μl of air in the vial was taken with a gas-tight syringe using the head-space technique, and then gas-tight. The test was performed by injecting a syringe into an injector.
{Total oxy-radical scavenging capacity (TOSC) value against peroxyl radiacls}Total Oxyradical Scavenging Ability for Peroxyl Radicals
{Total oxy-radical scavenging capacity (TOSC) value against peroxyl radiacls}
(Antioxidant)Antioxidant
(Antioxidant)
부탄올 추출물Black ginseng
Butanol extract
메탄올 추출물Black ginseng
Methanol extract
부탄올 추출물Red ginseng
Butanol extract
메탄올 추출물Red ginseng
Methanol extract
453 ± 88
{Total oxy-radical scavenging capacity (TOSC) value against peroxynitrite}Total Oxyradical Scavenging Ability for Peroxidation
{Total oxy-radical scavenging capacity (TOSC) value against peroxynitrite}
(Antioxidant)Antioxidant
(Antioxidant)
부탄올 추출물Black ginseng
Butanol extract
메탄올 추출물Black ginseng
Methanol extract
부탄올 추출물Red ginseng
Butanol extract
메탄올 추출물Red ginseng
Methanol extract
상기 실험결과, 홍삼 및 흑삼은 0.2mg/ml 농도 이하에서 퍼옥실 라디칼(peroxyl radicals) 및 과산화질산염(peroxynitrite)에 대해 모두 높은 항산화 활성을 나타냈다. As a result of the experiment, red ginseng and black ginseng showed high antioxidant activity against peroxyl radicals and peroxynitrite at 0.2 mg / ml or less.
퍼옥실 라디칼(Peroxyl radicals)에 대한 소거능(scavenging)은 홍삼 및 흑삼이 대등한 것으로 관찰되었다(표 2 참조). Scavenging of peroxyl radicals was observed to be comparable to red and black ginseng (see Table 2).
그러나 과산화질산염(peroxynitrite)에 대한 소거능(scavenging)은 흑삼 부탄올(butanol) 추출물 및 메탄올(methanol) 추출물이 홍삼 부탄올 추출물 및 메탄올 추출물에 비하여 약 1.7배의 높은 활성을 보였다(표 3 참조). However, the scavenging ability of peroxynitrite showed 1.7 times higher activity of black ginseng butanol extract and methanol extract than red ginseng butanol extract and methanol extract (see Table 3).
이러한 실험결과는 인삼을 숙성시키는 방법에 따라 조성물의 종류나 비율이 변하여 항산화 효과에 차이를 유발할 수 있음을 나타낸다.These experimental results indicate that the type or ratio of the composition may change depending on the method of aging ginseng, which may cause a difference in the antioxidant effect.
실험예Experimental Example 2. 2. 급성독성실험Acute Toxicity Test
대한실험동물센터에서 공급받은 6 주령의 특정병원체부재(specific pathogen-free, SPF) SD계 랫트를 사용하여 급성독성실험을 하기와 같이 실시하였다. Acute toxicity test was performed using 6-week-old specific pathogen-free (SPF) SD rats supplied from the Korean Experimental Animal Center as follows.
각 그룹 당 2마리씩의 동물에 상기 실시예 2의 흑삼 메탄올 추출물 및 흑삼 부탄올 추출물을 1g/㎏의 용량으로 1회 경구투여 하였다. Two animals of each group were orally administered to the black ginseng methanol extract and black ginseng butanol extract of Example 2 at a dose of 1 g / kg.
실험 물질 투여 후, 동물의 폐사여부, 임상증상 및 체중변화를 관찰하고 혈액학적 검사와 혈액생화학적 검사를 실시하였으며, 부검하여 육안으로 강장기와 흉강 장기의 이상여부를 관찰하였다.After administration of the test substance, mortality, clinical symptoms, and body weight changes were observed, and hematological and hematological examinations were performed.
그 실험결과, 실험 물질을 투여한 모든 동물에서 특이할 만한 임상증상이나 폐사된 동물은 없었으며, 체중변화, 혈액검사, 혈액생화학 검사 및 부검 소견 등에서도 독성변화는 관찰되지 않았다. As a result, no clinical symptoms or dead animals were found in all animals treated with the test substance, and no toxic changes were observed in weight changes, blood tests, blood biochemical tests, and autopsy findings.
이상의 결과, 본 발명의 추출물은 랫트에서 각각 1g/㎏까지도 독성변화를 나타내지 않았으며, 경구투여 최소치사량(LD50)은 1g/㎏이상인 안전한 물질로 판단되었다. As a result, the extract of the present invention did not show a change in toxicity even in rats up to 1 g / kg, respectively, the minimum lethal dose (LD 50 ) was determined to be a safe substance of more than 1 g / kg.
본 발명의 흑삼 추출물을 포함하는 약학조성물의 제제예를 설명하나, 본 발명은 이를 한정하고자 함이 아닌 단지 구체적으로 설명하고자 함이다.The preparation example of the pharmaceutical composition comprising the black ginseng extract of the present invention will be described, but the present invention is not intended to be limited thereto, but is intended to be described in detail.
제제예 1. 산제의 제조Formulation Example 1 Preparation of Powder
흑삼 추출물 300 mgBlack Ginseng Extract 300 mg
유당 100 mgLactose 100 mg
탈크 10 mgTalc 10 mg
상기의 성분들을 혼합하고 기밀포에 충진하여 산제를 제조한다.The above ingredients are mixed and filled in an airtight cloth to prepare a powder.
제제예 2. 정제의 제조Formulation Example 2 Preparation of Tablet
흑삼 추출물 50 mgBlack ginseng extract 50 mg
옥수수전분 100 mgCorn starch 100 mg
유당 100 mgLactose 100 mg
스테아린산 마그네슘 2 mg2 mg magnesium stearate
상기의 성분들을 혼합한 후 통상의 정제의 제조방법에 따라서 타정하여 정제를 제조한다.After mixing the above components, tablets are prepared by tableting according to a conventional method for preparing tablets.
제제예Formulation example 3. 캅셀제의 제조 3. Manufacture of capsule
흑삼 추출물 50 mgBlack ginseng extract 50 mg
옥수수전분 100 mgCorn starch 100 mg
유당 100 mgLactose 100 mg
스테아린산 마그네슘 2 mg2 mg magnesium stearate
통상의 캡슐제 제조방법에 따라 상기의 성분을 혼합하고 젤라틴 캡슐에 충전하여 캡슐제를 제조한다.According to a conventional capsule preparation method, the above ingredients are mixed and filled into gelatin capsules to prepare capsules.
제제예Formulation example 4. 주사제의 제조 4. Preparation of injections
흑삼 추출물 50 mgBlack ginseng extract 50 mg
주사용 멸균 증류수 적량Sterile sterilized water for injection
pH 조절제 적량pH adjuster
통상의 주사제의 제조방법에 따라 1 앰플당(2㎖) 상기의 성분 함량으로 제조한다.According to the conventional method for preparing an injection, the amount of the above ingredient is prepared per ampoule (2 ml).
제제예Formulation example 5. 5. 액제의Liquid 제조 Produce
흑삼 추출물 100 mgBlack Ginseng Extract 100 mg
이성화당 10 g10 g of isomerized sugar
만니톨 5 g5 g of mannitol
정제수 적량Purified water
통상의 액제의 제조방법에 따라 정제수에 각각의 성분을 가하여 용해시키고 레몬향을 적량 가한 다음 상기의 성분을 혼합한 다음 정제수를 가하여 전체를 정제수를 가하여 전체 100㎖로 조절한 후 갈색병에 충진하여 멸균시켜 액제를 제조한다.After dissolving each component in purified water according to the usual method of preparing a liquid solution, adding lemon flavor appropriately, mixing the above components, adding purified water, adjusting the whole to 100 ml by adding purified water, and then filling into a brown bottle. The solution is prepared by sterilization.
제제예Formulation example 6. 건강 식품의 제조 6. Manufacture of health food
흑삼 추출물 1000 ㎎Black Ginseng Extract 1000mg
비타민 혼합물 적량Vitamin mixture proper amount
비타민 A 아세테이트 70 ㎍70 μg of Vitamin A Acetate
비타민 E 1.0 ㎎Vitamin E 1.0 mg
비타민 B1 0.13 ㎎0.13 mg of vitamin B 1
비타민 B2 0.15 ㎎0.15 mg of vitamin B 2
비타민 B6 0.5 ㎎0.5 mg of vitamin B 6
비타민 B12 0.2 ㎍Vitamin B 12 0.2 g
비타민 C 10 ㎎Vitamin C 10 mg
비오틴 10 ㎍10 μg biotin
니코틴산아미드 1.7 ㎎Nicotinic Acid 1.7 mg
엽산 50 ㎍50 μg folic acid
판토텐산 칼슘 0.5 ㎎Calcium Pantothenate 0.5mg
무기질 혼합물 적량Mineral mixture
황산제1철 1.75 ㎎Ferrous Sulfate 1.75 mg
산화아연 0.82 ㎎Zinc Oxide 0.82 mg
탄산마그네슘 25.3 ㎎Magnesium carbonate 25.3 mg
제1인산칼륨 15 ㎎Potassium monophosphate 15 mg
제2인산칼슘 55 ㎎Dibasic calcium phosphate 55 mg
구연산칼륨 90 ㎎Potassium Citrate 90 mg
탄산칼슘 100 ㎎Calcium Carbonate 100 mg
염화마그네슘 24.8 ㎎Magnesium chloride 24.8 mg
상기의 비타민 및 미네랄 혼합물의 조성비는 비교적 건강식품에 적합한 성분을 바람직한 실시예로 혼합 조성하였지만, 그 배합비를 임의로 변형 실시하여도 무방하며, 통상의 건강식품 제조방법에 따라 상기의 성분을 혼합한 다음, 과립을 제조하고, 통상의 방법에 따라 건강식품 조성물 제조에 사용할 수 있다.Although the composition ratio of the above-mentioned vitamin and mineral mixture is comparatively mixed with a composition suitable for health food as a preferred embodiment, the compounding ratio may be arbitrarily modified, and the above ingredients are mixed according to a conventional method for producing healthy foods , Granules can be prepared and used in the manufacture of health food compositions according to conventional methods.
제제예Formulation example 7. 건강 음료의 제조 7. Manufacture of health drinks
흑삼 추출물 1000 ㎎Black Ginseng Extract 1000mg
구연산 1000 ㎎Citric acid 1000 mg
올리고당 100 g100 g oligosaccharides
매실농축액 2 gPlum concentrate 2 g
타우린 1 g1 g of taurine
정제수를 가하여 전체 900 ㎖Add 900 ml of purified water
통상의 건강음료 제조방법에 따라 상기의 성분을 혼합한 다음, 약 1시간 동안 85℃에서 교반 가열한 후, 만들어진 용액을 여과하여 멸균된 2ℓ 용기에 취득하여 밀봉 멸균한 뒤 냉장 보관한 다음 본 발명의 건강음료 조성물 제조에 사용한다. After mixing the above components according to a conventional healthy beverage production method, and then stirred and heated at 85 ℃ for about 1 hour, the resulting solution is filtered and obtained in a sterilized 2 L container, sealed sterilization and refrigerated and then stored in the present invention For the preparation of healthy beverage compositions.
상기 조성비는 비교적 기호음료에 적합한 성분을 바람직한 실시예로 혼합 조성하였지만 수요계층이나, 수요국가, 사용용도 등 지역적, 민족적 기호도에 따라서 그 배합비를 임의로 변형 실시하여도 무방하다.Although the compositional ratio is relatively mixed with a component suitable for a favorite drink, it is also possible to arbitrarily modify the compounding ratio according to the regional or national preference such as the demand class, the demanding country, and the use purpose.
상기와 같이, 본 발명은 인삼을 이용하여 제조한 흑삼으로부터 수득한 흑삼 추출물을 함유하는 조성물에 관한 것으로, 상기 조성물은 강한 항산화 효과를 나타내므로 항노화용 약학조성물 및 건강기능식품으로 유용하게 사용될 수 있다.As described above, the present invention relates to a composition containing a black ginseng extract obtained from black ginseng prepared using ginseng, the composition shows a strong antioxidant effect can be useful as an anti-aging pharmaceutical composition and health functional food .
Claims (5)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020060125472A KR101082262B1 (en) | 2006-12-11 | 2006-12-11 | Composition comprising an extract of black ginseng showing anti-aging activity |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020060125472A KR101082262B1 (en) | 2006-12-11 | 2006-12-11 | Composition comprising an extract of black ginseng showing anti-aging activity |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20080053658A KR20080053658A (en) | 2008-06-16 |
KR101082262B1 true KR101082262B1 (en) | 2011-11-09 |
Family
ID=39800862
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020060125472A KR101082262B1 (en) | 2006-12-11 | 2006-12-11 | Composition comprising an extract of black ginseng showing anti-aging activity |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR101082262B1 (en) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100496418B1 (en) | 2002-09-11 | 2005-06-28 | 한국파낙스제조(주) | Manufacturing method of black rootlets of ginseng |
KR100543862B1 (en) | 2005-08-01 | 2006-01-23 | (주) 흑삼코리아 | A black ginseng having excel content of active ingredient and the concentrate of black ginseng |
-
2006
- 2006-12-11 KR KR1020060125472A patent/KR101082262B1/en not_active IP Right Cessation
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100496418B1 (en) | 2002-09-11 | 2005-06-28 | 한국파낙스제조(주) | Manufacturing method of black rootlets of ginseng |
KR100543862B1 (en) | 2005-08-01 | 2006-01-23 | (주) 흑삼코리아 | A black ginseng having excel content of active ingredient and the concentrate of black ginseng |
Also Published As
Publication number | Publication date |
---|---|
KR20080053658A (en) | 2008-06-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101082181B1 (en) | A method for preparing novel black-red ginseng and the extract therefrom and the composition comprising the same | |
KR100754253B1 (en) | A novel process for preparing black ginseng and the composition comprising the same | |
KR100889950B1 (en) | A novel process for preparing red ginseng and the composition comprising the same | |
KR101992344B1 (en) | Manufacturing method of high quality red platycodon and red platycodon thereof | |
KR100921266B1 (en) | Method for producing red-ginseng extract | |
KR100868249B1 (en) | A pharmaceutical composition and health care food comprising novel black ginseng leaf and the extract thereof showing anti-aging activity prepared by novel process | |
KR20100130020A (en) | A composition comprising novel black ginseng without tumor promoting agents such as benzopyran and the extract thereof obtained by novel process | |
KR20090022456A (en) | Methods for preparing amino acid extract from red ginseng | |
KR101082173B1 (en) | A method for preparation of flower bud of black ginseng and a composition comprising the extract thereof showing anti-aging activity | |
KR101082262B1 (en) | Composition comprising an extract of black ginseng showing anti-aging activity | |
KR100781571B1 (en) | Pharmaceutical composition comprising an extract of novel black ginseng | |
KR100972941B1 (en) | Composition comprising an extract of black ginseng for preventing or treating hepatoma | |
KR101751608B1 (en) | Salvia miltiorrhiza Bunge extract with low-temperature enzymatic extraction and preparation method thereof | |
KR101833776B1 (en) | Composition for Preventing Alopecia and Improving Hair Growth Comprising the Extract of Anemarrhena Asphodeloides and Aralia Elata | |
KR101210748B1 (en) | Composition comprising the extract of Acanthopanax sessiliflorus and green tea for treating or alleviating hangover syndrome | |
KR100844991B1 (en) | A composition comprising the extract of black ginseng leaf showing anti-cancer activity | |
KR100638344B1 (en) | Composition comprising the crude drug extract for improving eye symptoms of VDT syndrome | |
KR101367885B1 (en) | A composition comprising the extract of combined herb of Panax ginseng and Vitis genus plant treating and preventing neuro-degenerative disease and enhancing memory power | |
KR101929664B1 (en) | Fermented-white ginseng extracts containing increased ginsenoside Rd, Rg3 and Rg5 and method thereof | |
KR20080016291A (en) | A composition comprising novel black ginseng and the extract thereof for the prevention and treatment of diabetes mellitus prepared by novel process | |
KR20130043767A (en) | A composition comprising the extract of processed panax genus plant for treating and preventing liver disease and hepato-protective activity | |
KR20130000017A (en) | Composition for preventing and treating diabetics containing active ingredients separated from sorghum | |
KR20130103097A (en) | Processed panax spp. plant extract with increased content ratio of ginsenoside rg5 or ginsenoside rk1, a process for the preparation thereof, and a composition comprising the same | |
KR20080056651A (en) | A composition comprising the processed extract of panax quinquefolium l. for the prevention and treatment of cancer | |
KR20120033443A (en) | Antifatigue composition comprising the extracts, fractions or isolated compounds of eisenia bicyclis and process for preparation thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
LAPS | Lapse due to unpaid annual fee |